Avacta Group Plc (AIM:AVCT)

Market Cap	126.32M
Revenue (ttm)	113.00K
Net Income (ttm)	-52.84M
Shares Out	388.68M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,504,158
Average Volume	2,389,725
Open	30.73
Previous Close	30.50
Day's Range	30.30 - 34.00
52-Week Range	26.00 - 86.40
Beta	-0.28
RSI	48.30
Earnings Date	May 29, 2025

About Avacta Group

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that driv...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 151
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: AVCT

Financial Performance

In 2024, Avacta Group's revenue was 113,000, a decrease of -96.04% compared to the previous year's 2.85 million. Losses were -52.84 million, 58.9% more than in 2023.